Ketamine is a synthetic compound first created in 1962 that has gone from operating-room anesthetic to one of the most studied molecules in modern psychiatry. Chemically derived from phencyclidine, it acts primarily by blocking a specific receptor in the brain, but decades of research have revealed that this description barely scratches the surface of what the molecule does. Its two mirror-image forms behave differently, its breakdown products may carry their own therapeutic effects, and its risks depend heavily on dose, duration, and route of delivery.
Where Ketamine Came From
Ketamine was synthesized in 1962 by Calvin Stevens at the Parke-Davis pharmaceutical laboratory, working from phencyclidine, a compound already known for its hallucinogenic and dissociative properties. The first human administration took place in 1964 at Jackson Prison in Michigan, where researchers noted a short-duration anesthesia accompanied by unusual dissociative effects. A patent for human use followed in 1966.1PubMed. History of Ketamine: An ancient molecule that is still popular today By the early 1970s, ketamine had become a battlefield anesthetic during the Vietnam War, valued because it could be injected into muscle without requiring an IV line and did not suppress breathing the way other anesthetics did. That respiratory safety profile remains one of its most distinctive advantages.
Two Mirror Images, Two Different Drugs
The ketamine molecule exists as two mirror-image forms, called enantiomers. Most clinical ketamine is a 50/50 mix of both, known as the racemic form. But the two halves are not equal. The S-form (esketamine) is roughly three times more potent as a painkiller and about one and a half times stronger as an anesthetic compared to the R-form (arketamine).2PubMed Central. Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms That potency difference is why esketamine was developed as a standalone drug for depression, approved as a nasal spray.
The R-form, arketamine, has its own appeal. At doses below the anesthetic threshold, it produces fewer of the dissociative and perceptual disturbances that make ketamine experiences unsettling for some patients.3PubMed. Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers This matters because dissociation is one of the main reasons patients discontinue ketamine treatment. Arketamine is now being studied as a potentially gentler antidepressant, though it has not yet been approved for that purpose anywhere in the world.
How Ketamine Acts in the Brain
Ketamine’s best-known action is blocking NMDA receptors, which are docking sites for the neurotransmitter glutamate. When ketamine plugs into these receptors, it dampens a major excitatory signaling pathway, producing the anesthetic and dissociative effects the drug is known for. But research over the past two decades has complicated that tidy story. Work on ketamine’s mood-altering effects has questioned whether NMDA blockade alone explains them, pointing to a cascade of downstream events that may matter more.4PubMed Central. Ketamine: NMDA Receptors and Beyond
One leading theory focuses on what happens after the initial NMDA block. At sub-anesthetic doses, ketamine appears to preferentially silence inhibitory brain cells (interneurons), which paradoxically unleashes a burst of glutamate activity on a different type of receptor called AMPA. That burst triggers a signaling chain that ramps up production of brain-derived neurotrophic factor (BDNF), a protein that promotes the growth and strengthening of synaptic connections. In animal studies, ketamine rapidly activates a growth pathway called mTOR, increasing levels of key signaling proteins within hours, an effect that persists for at least 72 hours.5PubMed Central. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity When researchers block BDNF with an antibody or knock out the gene for it, ketamine’s antidepressant-like effects in animals disappear, suggesting BDNF is not just a bystander but a necessary ingredient.
Brain imaging in humans offers a complementary view. After a ketamine dose, functional connectivity in the medial prefrontal cortex drops, while connectivity in parietal regions increases. Simultaneously, brainwave activity shifts, with more energy moving into slow-wave and fast gamma frequencies.6PubMed Central. Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI/EEG study The prefrontal cortex is heavily involved in the default mode network, the brain circuitry associated with self-referential thought and rumination. A temporary loosening of that network may help explain both the dissociative “out of body” experience and the break from depressive thought loops that many patients report.
Ketamine as an Anesthetic and Emergency Tool
Ketamine’s original purpose remains one of its most important. For inducing anesthesia, the racemic mixture is given intravenously at doses in the range of 1–2 mg/kg, producing dissociative anesthesia within one to two minutes. To keep someone under, a continuous drip in the range of 1–6 mg/kg per hour is used. The S-form requires roughly half those doses.7PubMed Central. Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms
What makes ketamine stand out among anesthetics is its effect on breathing. Most drugs that render a person unconscious also suppress the respiratory drive and relax the muscles that keep the airway open, a combination that can be dangerous without ventilator support. Ketamine does the opposite: it stimulates breathing. In direct comparison with propofol, a widely used anesthetic, ketamine produced higher respiratory rates, larger breaths, and lower carbon dioxide levels, all signs that the body’s breathing machinery was working harder, not less.8PubMed Central. Ketamine Activates Breathing and Abolishes the Coupling between Loss of Consciousness and Upper Airway Dilator Muscle Dysfunction This property makes ketamine invaluable in emergency rooms, field hospitals, and settings where intubation equipment or a trained anesthesiologist may not be available. It is also frequently used for procedural sedation in children, whose smaller airways make respiratory depression especially risky.
At lower intravenous doses of about 0.25–0.5 mg/kg, ketamine provides pain relief comparable to morphine or fentanyl without the respiratory depression those opioids carry. In emergency and pre-hospital settings, that trade-off is significant: paramedics can manage severe pain without the risk of a patient stopping breathing during transport.
The Antidepressant Breakthrough
The finding that changed ketamine’s trajectory arrived in the early 2000s, when researchers reported that a single low-dose infusion could lift severe depression within hours, not the weeks that conventional antidepressants require. Much of the subsequent research has focused on treatment-resistant depression, the roughly one-third of depressed patients whose symptoms do not respond adequately to first-line medications.
How the drug is delivered turns out to matter. Intravenous racemic ketamine offers near-complete and immediate bioavailability, meaning essentially all of it reaches the bloodstream and the brain very quickly. The FDA-approved intranasal esketamine spray, by contrast, achieves a mean bioavailability of around 54%, with peak blood levels arriving at roughly 40 minutes after dosing.9PubMed Central. Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis That slower, partial absorption may explain why meta-analytic comparisons tend to show a numerical trend favoring IV racemic ketamine over intranasal esketamine for depression outcomes, though both show meaningful effects. The IV route requires medical supervision with monitoring, while the nasal spray is administered in a certified healthcare setting under observation for at least two hours.
Rapid Reduction of Suicidal Thinking
One of ketamine’s most striking clinical effects is how fast it can reduce suicidal ideation, an area where conventional treatments are painfully slow. A meta-analysis pooling individual patient data found that a single ketamine dose produced moderate-to-large reductions in suicidal thinking within 24 hours, and that this effect was partially independent of any general improvement in depressive symptoms.10PubMed Central. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis That last point is worth emphasizing: the reduction in suicidal thoughts was not simply a side effect of feeling less depressed overall. Something about ketamine appears to target suicidal ideation more directly.
In a randomized trial comparing ketamine to midazolam (a sedative used as an active control to partially blind participants), about 55% of the ketamine group had their suicidal ideation scores cut in half by day one, compared to 30% in the midazolam group.11PubMed Central. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial A more recent meta-analysis found that after the first day, ketamine was significantly more effective than placebo, esketamine, and midazolam for reducing suicidal ideation, with benefits persisting out to nearly a month in some comparisons.12Translational Psychiatry. A meta-analysis of the effects of ketamine on suicidal ideation in depression patients The challenge remains that these effects are temporary. Without repeated dosing or integration with other treatments, suicidal ideation typically returns within days to weeks.
A Metabolite That May Work on Its Own
Once in the body, ketamine is broken down into several metabolites, and one of them has drawn intense scientific interest: (2R,6R)-hydroxynorketamine, often shortened to (2R,6R)-HNK. In rodent models of depression, this metabolite reduced behavioral despair, anhedonia, anxiety, and social avoidance in both stressed and unstressed animals.13PubMed. The antidepressant potential of (2R,6R)-hydroxynorketamine: A detailed review of pre-clinical findings What makes this especially interesting is that (2R,6R)-HNK does not appear to block NMDA receptors at the concentrations that produce antidepressant-like effects.14Proceedings of the National Academy of Sciences. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function Instead, its mechanism appears to involve a different glutamate receptor, mGlu2.15Proceedings of the National Academy of Sciences. (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions
If (2R,6R)-HNK can be developed into a standalone drug, it could theoretically offer ketamine’s antidepressant benefits without the dissociation, sedation, and abuse potential that come from NMDA blockade. In animal safety testing, doses up to 160 mg/kg given intravenously produced no signs of brain-cell damage or inflammation.16PubMed Central. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801 Human trials are still in early stages, but the metabolite represents one of the more promising leads in the search for next-generation rapid-acting antidepressants.
Ketamine for Chronic Pain
Beyond anesthesia and psychiatry, ketamine has carved out a role in chronic pain management, particularly for complex regional pain syndrome (CRPS), a condition characterized by severe, often burning pain that typically follows an injury and persists far beyond normal healing. CRPS involves a kind of central sensitization, where the nervous system amplifies pain signals, and NMDA receptors play a role in that amplification. Intravenous ketamine infusions have been used for CRPS when other treatments fail, with published case series and reviews documenting variable but sometimes significant pain relief.17PubMed Central. Ketamine for Complex Regional Pain Syndrome: A Narrative Review Highlighting Dosing Practices and Treatment Response The dosing protocols vary widely across clinics, and the duration of relief is unpredictable, ranging from days to months. There is no consensus on the ideal regimen, which means patients exploring this option face significant variation in what they are offered.
Bladder Damage and Other Urological Risks
One of ketamine’s most serious adverse effects involves the urinary tract, and it is most clearly documented among people who use the drug recreationally at high doses over extended periods. Ketamine metabolites cause severe inflammation of the bladder lining, damaging the protective barrier of the urothelium and eventually leading to fibrosis of the bladder wall.18PubMed Central. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis Symptoms typically start with urinary pain and increased frequency, and can progress to severely reduced bladder capacity, ureteral narrowing, and in the worst cases, kidney failure.19PubMed Central. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug
Animal research has illuminated the mechanism: ketamine triggers oxidative stress through both mitochondrial and endoplasmic-reticulum pathways, leading to programmed cell death in bladder tissue and breakdown of the proteins that hold the urothelial barrier together.20American Journal of Physiology-Renal Physiology. Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum The damage is dose- and duration-dependent. Whether the lower, less frequent doses used in clinical depression treatment carry meaningful bladder risk is not yet clear, but the concern is real enough that patients on repeated ketamine infusions are commonly advised to report any urinary symptoms promptly.
Does Ketamine Damage the Brain?
The question of neurotoxicity is one of the more debated aspects of ketamine science. In the 1980s and 1990s, studies on a related NMDA-blocking compound called MK-801 showed it could cause a distinctive type of brain-cell injury known as Olney lesions, named after the neuroscientist who described them. This raised the worry that any NMDA blocker, ketamine included, might do the same at high enough doses.
The animal evidence, however, is more reassuring at clinically relevant doses. In a direct comparison, a single dose of ketamine up to 60 mg/kg in rats produced no neuronal damage, no cell death, and no activation of the brain’s immune cells.21PubMed Central. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801 At the same time, evidence from people with ketamine use disorders, who tend to use far higher doses far more often than any clinical protocol calls for, does suggest potential brain changes. A review of the literature concluded that chronic high-dose ketamine exposure exceeding what is recommended for depression treatment may be associated with brain pathology, but it remains unknown whether the repeated low doses used clinically carry the same risk.22PubMed. A review of potential neuropathological changes associated with ketamine
There is also a cognitive question. In a rat model, short-term ketamine treatment did not produce significant cognitive changes, but long-term administration impaired performance on a recognition memory task and increased repetitive behaviors associated with psychosis-like states.23PubMed. Cognitive and psychotic effects of ketamine “short- vs. long-term” therapy in a rat model of depression: Hippocampal TrkB/Akt/GSK-3β/mTOR/autophagy trajectories Translating rat findings to human clinical use requires caution, but the pattern suggests a meaningful difference between occasional and prolonged exposure.
Dependence and the Addiction Paradox
Ketamine can be addictive. People who use it recreationally sometimes develop a pattern resembling cocaine dependence, with intense craving and high tolerance but without the obvious physical withdrawal seen with opioids or alcohol.24PubMed. The nonmedical use of ketamine, part two: A review of problem use and dependence The mechanisms likely involve ketamine’s effects on dopamine and opioid systems, in addition to its distinctive dissociative and psychedelic qualities, which some users find psychologically compelling.
This creates a genuine paradox: ketamine is also being studied as a treatment for addiction itself. The same synapse-building cascade that underlies its antidepressant effects may help rewrite the maladaptive brain circuits that drive drug-seeking behavior. In regions like the prefrontal cortex and the nucleus accumbens, addiction involves pathologically strong connections between cues and reward. Ketamine-induced new synapse formation in these same circuits may weaken those connections and restore the prefrontal cortex’s ability to put the brakes on craving.25PubMed Central. Treating addiction with an addictive drug: the ketamine paradox revisited Early clinical work has explored ketamine-assisted therapy for alcohol and cocaine use disorders, though this line of research remains preliminary. The tension between ketamine’s therapeutic potential and its own abuse liability is something the field is actively grappling with, and the answer likely depends on dose, context, and supervision.
Ketamine-Assisted Psychotherapy
A growing number of clinics are pairing ketamine with structured psychotherapy, an approach sometimes called ketamine-assisted therapy (KAT). The idea is that the window of heightened neuroplasticity and reduced psychological defenses that ketamine opens can make therapy sessions more productive. Some models frame ketamine explicitly as an amplifier of the therapeutic process rather than the primary driver of change, with group rituals, intentional setting, and relational therapy doing much of the heavy lifting.26PubMed Central. A clinical protocol for group-based ketamine-assisted therapy in a community of practice: the Roots To Thrive model
The evidence base for KAT is still developing. Most published studies are small, open-label, or use highly variable protocols. What constitutes “therapy” in these settings ranges from brief check-ins before and after a ketamine session to multi-week structured curricula involving group processes and preparation work. Whether the psychotherapy component adds durable benefit beyond what ketamine alone provides is a question that larger, controlled trials will need to answer.
Regulation and Access
Ketamine occupies an unusual regulatory position. In the United States it is a Schedule III controlled substance, meaning it has accepted medical use but carries some potential for abuse. This is notably less restrictive than Schedule I or II, which makes it available for off-label prescribing. Doctors can legally prescribe intravenous or oral ketamine for depression, even though that use has not received specific FDA approval. The only FDA-approved ketamine-related product for depression is intranasal esketamine (Spravato), which must be administered in a certified healthcare facility. Globally, regulations vary widely: some countries have moved toward tighter controls in response to recreational use, while others continue to list ketamine primarily as an essential anesthetic medicine.27PubMed. Ketamine and international regulations The World Health Organization has repeatedly resisted calls to place ketamine under international scheduling, citing its critical role in anesthesia in low-resource settings where alternatives may not be available.
New Derivatives on the Horizon
Researchers are trying to build molecules that keep ketamine’s benefits while shedding its problems. One recent approach involved creating a series of modified ketamine compounds, adding chemical groups to the molecule and testing whether the resulting derivatives retained pain-relieving and antidepressant activity. One of these, identified as compound k1, matched ketamine’s painkilling potency and showed strong antidepressant-like effects in multiple animal behavioral tests. The striking finding was that k1 produced essentially no psychosis-like side effects compared to ketamine, and it was effective when given orally rather than by injection.28PubMed. Discovery of a Novel Orally Active Ketamine Derivative with Dual Analgesic and Antidepressant Activities, Lacking Psychomimetic Effects An oral compound that relieves pain and lifts depression without making you dissociate would be a meaningful advance, though the path from a promising animal study to a drug you can pick up at a pharmacy is long. Combined with the metabolite research described earlier, the broader picture is one of a field trying to unbundle ketamine’s pharmacology, isolating the therapeutic threads from the experiential and addictive ones.